You are here: Industry Insights > AstraZeneca

News List

Fresh off new Farxiga data, AstraZeneca diabetes push points up cardiovascular, renal risks fiercepharma
April 02, 2019
AstraZeneca has been pumping dollars into studying its Type 2 diabetes drugs and their ability to stave off complications like heart disease and kidney problems……
Pharma taps new CEO just as it unveils a big tie-up with AstraZeneca fiercepharma
April 02, 2019
Only a month after making one set of senior-level management changes, Daiichi Sankyo has decided it’s the right time to change its CEO as well.
Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients fiercepharma
April 02, 2019
AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.
EU approves AZ' Forxiga for type I diabetes pharmatimes
March 27, 2019
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC) for type I diabetes.
AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes fiercepharma
March 19, 2019
AstraZeneca is stepping up its case for its SGLT2 diabetes drug Farxiga with new numbersshowing it can cut the risk of serious cardiovascular complications in heart attack and heart failure patients.
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis worldpharmanews
March 19, 2019
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib
AZ’ Farxiga shows CV benefit in diabetes patients pharmatimes
March 19, 2019
Trial data show that AstraZeneca’s Farxiga (dapagliflozin) cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack.
AstraZeneca and Seres Therapeutics to study new cancer therapy process pharmaceutical-technology
March 13, 2019
AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy of cancer immunotherapy.
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca pharmafocusasia
March 12, 2019
Seres Therapeutics, Inc. announced a three-year research collaboration with AstraZeneca.
Keytruda could get patient-friendly 6 week dosing schedule in EU pharmaphorum
March 07, 2019
US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pembrolizumab) cancer immunotherapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page